SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics (Nasdaq: MBRX) announced today that Dr. Paul van Poelje will give an oral presentation entitled, “MB07803, a Prodrug of a Second Generation Fructose-1,6-Bisphosphatase Inhibitor, Lowers Blood Glucose in Diabetic Rodents and in Cynomolgus Monkeys,” at the 68th Annual Scientific Sessions of the American Diabetes Association (ADA). Dr. van Poelje’s presentation is scheduled for Monday, June 9 at 6:00 pm. The Company will also be presenting a poster during ADA entitled “Glucagon Action is a Major Determinant of Hyperglycemia in the Fasted, Fed and Postprandial States of Animal Models of Type 2 Diabetes,” which will be on display during the general poster session.
